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1. Introduction 
The mortality rate of severe sepsis and septic shock has remain high and always has been 
recognized as one of the most common cause of death worldwide. On the other hand, new 
interventions has been shown to decrease the complications of this syndrome, even 
reducing the percent of deaths from over 50% to 30-40% in some studies. 
In this chapter, we will discuss some of these therapies including the most important studies 
leading to better outcomes in the treatment of the above condition. 
2. Diagnosis 
So far there is no definitive test for the diagnosis of severe sepsis or septic shock. When the 
human body is exposed to an insult, whether caused by bacteria, trauma, burn, or drug 
overdose, the individual tends to respond differently depending on their health status and 
the presence or absence of co-morbidities. Despite no specific test available, there are certain 
findings that lead us to the diagnosis. These include tachycardia, tachypnea, leukocytosis or 
leucopenia, fever or hypothermia; all of them are basically criterias defining the Systemic 
Inflammatory Response Syndrome (SIRS). In addition, the presence of altered mental status, 
hyperbilirubinemia, metabolic acidosis or respiratory alkalosis and thrombocytopenia could 
also be useful. 
Severe sepsis is known as an acute organ dysfunction secondary to infection. When 
evaluating a patient with this syndrome time becomes our worst enemy. The organism/s 
responsible for the acute illness should be identified within the first hours. Appropriate 
cultures should be obtained before antimicrobial therapy is initiated to confirm the presence 
of infection and proceed with de-escalation of antibiotic therapy after a susceptibility profile 
is available. Two quantitative blood cultures should be taken and in patients with 
indwelling catheters for more than 48 hours, at least one blood culture should be drawn 
through each lumen of the vascular access [1]. When the same organism is recovered from 
both cultures, the likelihood that the organism is causing the severe sepsis is enhanced. 
Quantitative cultures of other body sites, such as urine, cerebrospinal fluid, wounds and /or 
respiratory secretions should also be obtained if they are considered to be the source of 
infection. It is important to understand that obtaining cultures before the initiation of 
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therapy should only be done if not associated with significant delay in antibiotic 
administration.  
Imaging studies might also be necessary to identify the source of infection, especially when 
the presence of foreign body or drainage is suspected to be the cause of severe sepsis. 
However, some patients may be too unstable to undergo invasive procedures or be 
transported outside the intensive care unit. In such cases bedside ultrasound can be useful. 
The potential role of biomarkers in the diagnosis of severe sepsis remains unclear. The use 
of pro-calcitonin level has demonstrated controversial results since it can be altered in 
patients with an acute inflammatory process other than infection [2]. In the near future, it is 
expected that rapid diagnostic methods, such as polymerase chain reaction, be available for 
quicker identification of pathogens and antimicrobial resistance patterns [3]. 
3. Source control 
Source control is known as the rapid diagnosis of the specific body site of infection 
amenable to proceed with control measures such as abscess drainage, debridement of 
infected necrotic tissue and removal of a potentially infected device. Possible infectious foci 
include: intra-abdominal abscess, intestinal infarction and/or gastrointestinal perforation, 
cholangitis, pyelonephritis, empyema and septic arthritis. Identification of these sites of 
infection should be within the first six hours of presentation [4,5]. 
When source control is required minimally invasive interventions should be employed. For 
example, performing percutaneous drainage rather than surgical intervention of an abscess 
[6]. If less invasive approaches are inadequate or there is uncertainty about the diagnosis, 
then more aggressive measures should be considered. When making such decisions the 
benefits versus risks as well as the patient’s preferences and clinician’s expertise must be 
considered [7].  
When an intravascular access device has been identified as the possible cause of severe 
sepsis removal of the device should be done after other vascular access has been established 
[8,9]. Special attention should be given when the suspected source of infection is a 
peripancreatic necrosis. Definitive intervention should be delayed until adequate 
demarcation of viable and non-viable tissue has been made. In this case endoscopic rather 
than surgical drainage of biliary tree should be considered taking into consideration what 
represents the least physiologic insult for the patient [10]. 
4. Antibiotic therapy 
Administration of antibiotics is considered as important as establishing a vascular access 
and giving fluid resuscitation. Therapy should be started within the first hour of recognition 
of septic shock. In some cases this may require additional vascular access, however this 
shouldn’t represent a delay in the infusion of antibiotics since this has been associated with 
increased mortality [11, 12]. The choice of empirical antibiotics will depend on patient’s 
history, including drug intolerance, co-morbidities, the clinical syndrome and susceptibility 
patterns of pathogens in the hospital, community and those that have previously infected 
the individual. Recently used antibiotics should definitely be avoided.  
Another consideration is whether fungal infection with Candida species is the cause of 
sepsis. Risk factors for candidemia include: central venous catheters, total parenteral 
nutrition, broad- spectrum antibiotics, high APACHE scores ( Acute Physiology and 
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Chronic Health Evaluation II), acute renal failure, prior surgery ( particularly abdominal 
surgery), gastrointestinal perforations and anastomotic leaks [13, 14, 15 ]. 
Immunocompromised patients such as those with hematologic malignancies, recipients of 
solid organ or hematopoietic stem cell transplants and those receiving chemotherapy are 
also at increased risk of candidemia [16]. 
All patients with septic shock should be treated initially with broad-spectrum antibiotics to 
cover the most common or likely pathogens. It has been demonstrated that failure to initiate 
appropriate therapy against the pathogen that is later identified as the cause of infection is 
associated with increased morbidity and mortality [17, 18]. Therapy should be re-evaluated 
on a daily basis for four reasons: to optimize activity, to prevent the development of 
resistance, and, to reduce toxicity and costs. 
Combination therapy should be given to those patients with risk factors for Pseudomonas 
infection and neutropenia, defined as an absolute neutrophil count (ANC) less than 1500. 
Although clinical evidence has failed to demonstrate that combination therapy produces 
superior clinical outcome for individual pathogens in a particular patient group, 
combination therapies do produce in vitro synergy against pathogens in some models [19, 
20, 21, 22]. The rationale in administering combination therapy for suspected Pseudomonas 
infection is to increase the likelihood that at least one drug will be effective against that 
strain. This intervention has demonstrated to have a positive effect on outcome [23].  
Duration of therapy should not exceed more than three to five days and de-escalation to 
single therapy should be performed as soon as susceptibility profiles are available. 
Narrowing the spectrum of antibiotic coverage and reducing the duration of therapy will 
decrease the possibility that the patient develops superinfections with pathogens or resistant 
organisms such as Candida species, Clostridium dificile, or vancomycin-resistant Enterococcus 
faecium. Therapy should be prolonged from seven to ten days in patients with slow clinical 
response and those who are immunocompromised or have a source of infection that cannot 
be controlled. If the cause of the clinical syndrome has been confirmed to be of noninfectious 
etiology, antibiotic therapy should discontinue immediately. This will decrease the 
likelihood that the patient becomes infected with drug resistant pathogens.  
5. Hemodynamic management in severe sepsis and septic shock 
Early sepsis signs are very difficult to diagnose,usually with nonspecific presentations. 
Patient who arrives with an unapparent infection can progress to a lethal form of disease. 
In 1992 The Society of Critical Care Medicine Conference consensus defined sepsis as a 
systemic inflammatory response that includes 2 or more clinical findings: temperature, 
respiratory rate, heart rate and white blood cell count in the setting of presumed or a 
documented infection [24].  
Severe sepsis is hallmarked by concomitant organ hypoperfusion or dysfunction [25,26,27].  
Sepsis induced hypotension is defined as a systolic blood pressure (SBP) < 90mmhg or mean 
arterial pressure < 65mmhg or SBP decease >40mmhg or 2SD below normal for age in 
absence of other cause of hypotension. Septic shock is defined as sepsis induced 
hypotension persisting despite adequate fluid resuscitation basically requiring vasoactive 
drugs. 
Early recognition of sepsis with integrated approach screening, triggering evidence-based 
protocolized care, is anticipated to reduce sepsis morbidity and mortality [28]. The 
Surviving Sepsis Campaign (SSC) provided some of the best clinical evidence for the 
management of severe sepsis and septic shock.  
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6. Initial resuscitation 
Patients with septic shock often require early and vigorous resuscitation with an integrated 
approach directed to rapid restoring systemic oxygen delivery and improving tissue 
oxygenation.  
The first priority involves stabilization of the airway and breathing,with supplemental 
oxygen and if necessary institution of mechanical ventilation.  
Second assessment of perfusion should be done (hypotension persisting after initial fluid 
challenge, blood lactate ≥ 4mmmol/L). Once hypoperfusion is recognized, early restoration 
of perfusion is necessary to limit secondary organ dysfunction and reduce mortality. During 
the first 6 hours of resuscitation, the goals should include: Central venous pressure 8-12mm 
Hg with a Mean Arterial Pressure (MAP) over 65mmHg,a urine output ≥ 0.5ml/kg/hr and 
finally a Central venous (superior vena cava) or mixed venous oxygen saturation ≥70% or ≥ ͸ͷ% respectively. If Svo2 is less than 70%, packed of red blood cells (PRBC) are transfuse 
to achieve an hematocrit level of 30%. If central venous pressure, MAP and hematocrit were 
optimized and Svo2/ScVo2 remained below 70% dobutamine is recommended to increase 
cardiac output and oxygen delivery. 
The early goal directed therapy has been shown to improved survival for emergency 
department (ED) patients with severe sepsis and septic shock. This evidence comes from a 
randomized controlled single center trial that assigned 253 patients with severe sepsis or 
septic shock to receive protocolized early goal directed therapy during the first 6 hours in 
ED or to receive standard therapy before admission in ICU. These resuscitation goals 
reduced the in hospital mortality from 46.5% to 30.5% (P=. 009), a 28 days mortality rate 
(p=0.1) and at 60 day (p=0.3) [28]. 
In 2004 the international group experts published first internationally accepted guidelines 
[29].Eventually from 2006 to 2007 the group met again to update the guidelines using new 
evidence [30]. Central venous pressure is currently commonly used as guide for 
resuscitation, although there are recognized limitations to ventricular filling pressures 
estimated as surrogate for fluid resuscitations [31, 32]. In mechanical ventilated patient 
target CVP of 12 to 15 mmHg is recommended to account for impediment of filling due to 
increase intrathoracic pressure [33]. Other cases to consider higher CVP include increased 
abdominal pressure and diastolic dysfunction [34]. 
The MAP is the most powerful predictor of mortality, commonly used as an indicator of 
perfusion pressure [35]. Current recommended levels are between 60-65 mmHg in view of 
adequate autoregulation of blood flow to vital organs [36].  
Oxygen is delivered to the tissues as a product of cardiac output (heart rate x stroke volume) 
and oxygen content (hemoglobin oxygen saturation x hemoglobin x 1.34) + (partial pressure 
of oxygen x .003). The tissues extract a percentage of the delivered for cellular respiration 
and the remaining returns to venous circulations. This amount can be measure from 
pulmonary artery (SvO2, mixed venous oxygen saturation) or by central venous circulation 
(central oxygen saturation). ScvO2 is only measure with a pulmonary catheter. However, 
the ScvO2 can be obtained by central insertion of the superior vena cava or right atrium. 
Pulmonary artery catheter for hemodynamic monitoring and mixed venous saturation has 
not shown any difference in outcome [37, 38] but it is used in selected cases. 
The measurement of Scvo2 is 5-6% higher than Sv02, but some studies has shown excellent 
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7. Fluid therapy 
Septic shock is associated with substantial volume depletion and myocardial dysfunction. 
The ventricular filling pressure is usually low due to an increase in external loses from 
gastrointestinal or urinary tracts, bleeding, skin surface or internal loses due to exudation or 
transudation of bloody fluids. This leads to a generalized vasodilatation and peripheral 
blood pooling, consequently decreasing the intravascular volume. Adequate fluid 
resuscitation therefore is one of the cornerstones of the management of septic shock. The 
aim is the restoration of intravascular fluid volume, reestablish effective tissue perfusion, 
increase cardiac output and systemic oxygen delivery. 
The outcomes advantages between crystalloid and colloids solutions continue to remain 
unsolved. The recent sepsis campaign guidelines cannot recommend one type or another. 
The Saline versus Albumin Fluid Evaluation (SAFE),a multicenter randomized trial study 
showed no difference in 28 day all mortality cause, organ dysfunction, duration of 
mechanical ventilation, day of renal replacement, hospital or ICU length of stay [41].  
However, other study compared 10% pentastarch (a low molecular weight hydroxyethyl 
starch) with ringer’s lactate and the first therapy was associated with higher rates of renal 
replacement therapy [42].  
As the volume of distribution is much large for crystalloids than for colloids, the use of 
crystalloids for resuscitation requires more fluid and infusion periods to achieve comparable 
hemodynamic endpoints. Though less colloid is requires, volume expansion with colloid is 
more expensive.The fluid challenge in patient with suspected hypovolemia may be give at 
rate of 500-1000ml of crystalloids or 300-500ml of colloids over 30 min and repeated on 
response (blood pressure, heart rate, urine output) and tolerance (evidence of intravascular 
fluid overload). 
Since the validation of CVP measurements in patients with sepsis is widely debated, other 
methods has emerged to assess fluids responsiveness. Echocardiography can be use to 
estimate Left ventricular End Diastolic volume but it is skill operator dependant [43]. Pulse 
Pressure Variation (PPV) during pressure breath can be used to predict responsiveness 
cardiac output to change preload [44]. PPV in mechanical ventilated patient is useful for 
assessing preload responsiveness [45]. 
Other controversial topics are the fact that excessive amount of fluid may be harmful to the 
patients with septic shock. Multiple studies have correlated positive fluid balance with 
reduces survival in ARDS [46] and sepsis [47]. Other study of 87 patients in mechanical 
ventilation showed that positive fluid balance were associated with failure of spontaneous 
breathing trials [48].  
A prospective study, The Fluid and Catheter Treatment Trial (FACTT) randomized 1,001 
patients with acute lung injury or ARDS to conservative (CVP<4mm Hg or pulmonary 
artery occlusion pressure [PAOP], <8mm Hg) vs. liberal (CVP, 10 to 14 mmHg, or PAOP, 14 
to 18mm Hg) fluid management and concluded that there was no mortality difference at 60 
days, but the conservative fluid strategies improved lung function, ventilator free days and 
reduce ICU length of stay [49].  
A new retrospective study review from the Vasopressin in Septic shock trial (VASST) in which 
was analyzed the positive fluid balance and determined correlation with CVP at 12hrs and 
during subsequent days. The study found increase mortality with positive fluid balance early 
in resuscitation and cumulative for 4 days. The CVP may be use as a gauge to fluid balance 
<12hrs, but becomes an unreliable marker of fluid balance thereafter. The overall data suggest 
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the optimal survival occurred at CVP of 8mmHg and positive fluid balance of 3 l during first 
12hr; however a randomized control studies is necessary to prove this [50].  
The approach of fluid resuscitation in sepsis shock patients suggest that should be liberal in 
the first 6h of acute resuscitation, guided by Svo2 or Scvo2. Once the patient is adequately 
resuscitated, fluids should be hold without the necessity of maintenance therapy. The 
intravascular status should be continuing monitoring with physical examination with 
observation of sign of hypoperfusion, weight, input and output chart and other measures [51]. 
8. Vasoactive therapy 
When the fluid administration fails to restore an adequate arterial pressure and organ 
perfusion , a vasoactive agent should be started. The ultimate goals are to restore effective 
tissue perfusion and normalize cellular metabolism. 
In shock state, the estimation of blood pressure using a cuff may be inaccurate and the use 
of arterial catheterization provides more precise and reproducible measurements of arterial 
pressure [52].  
Most experts recommend a MAP ≥ 65 mm Hg.  
9. Norepinephrine 
Norepinephrine is the endogenous mediator of the sympathetic system having a strong ǂ-
adrenergic activity with less ǃ-adrenergic effects.It increases MAP by vasoconstriction, with 
small (10-15%) increase in cardiac output and stroke volume [53-58] .Filling pressure is 
either unchanged[59] or modestly increased (1-3 mm Hg) [54-57]. 
In open labels trials, norepinephrine at doses ranges 0.01 to 3.3µg/kg/min has 
demonstrated to increase MAP in patients who remained hypotensive after fluid 
resuscitation and dopamine [54-56 , 58, 60, 64-65].  
A randomized trial compared vasopressor agents in 32 resuscitated septic patients in which 
either dopamine or norepinephrine were given to keep homodynamic derangements. 
Dopamine was successful only in 31% vs. 93% treated with norepinephrine [63].  
Another larger multicenter randomized trial study, which compared dopamine vs. 
norepinephrine for treatment for any kind of shock (cardiogenic, hypovolemic, septic), 
found no significant death rate at 28 days.However, there were more arrhythmic events 
among patients treated with dopamine.Also, patients who suffered cardiogenic shock and 
were managed with dopamine had an increase mortality rate at 28 days. This and other 
studies suggested that norepinephrine is a safer drug in cardiogenic shock and myocardial 
infarction patients due to tachyphylaxis [67]. 
Other important multivariate analysis included 97 septic shock patients and was statistically 
significant for a reduced mortality by the use of the norepinephrine. The use of high use 
dopamine, epinephrinephrine or dobutamine had no significant effect [68].  
The studies of norepinephrine with splanchnic blood flow in septic patient have mixed 
results. A recent one compared norepinephrine, dopamine and epinephrine for septic shock 
and there was no significant difference between them [69].  
10. Dopamine 
Dopamine has predominantly ǃ-adrenergic effects in low to moderate dose ranges (up to 10 
μg/kg per minute). Higher doses cause ǂ-adrenergic predominance leading to arterial 
vasoconstriction and increase blood pressure. 
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It may be useful in patients with decrease systolic dysfunction but causes more arrhythmias 
than norepinephrine [70]. Although is has shown diuretic properties,it is not recommended for 
above purposes [71] probably due to its neuroendocrine effects,which may interfere with 
prolactin, thyroid, pituitary function and some of the immunosuppressive functions [72-73].  
Moreover, the use of Dopamine at “renal dose” has been discouraged due to ample 
evidence in meta-analysis and high quality prospective trial .An important one included 328 
criticall ill patients with early renal dysfunction and were separated in groups for low dose 
dopamine or placebo. No difference was found in the primary outcome (peak serum 
creatinine level, need for renal replacement and urine output). Other variables such as 
survival or hospital length of stay were unremarkable as well. 
Multiple recent studies has shown more detrimental effects with Dopamine.For example, 
the use of dopamine was associated with an increased mortality in patients with shock in a 
prospective multicenter observational study of 198 Europeans ICU [74].  
In conclusion, many experts have recognized that Dopamine should not be the first 
vasoactive drug in patients in shock and some of them recommended that should not be 
used anymore in patients with septic shock. 
11. Epinephrine 
Epinephrine has potent ǃ1-ǃ2 and ǂ1-adrenegic activity, although the elevated MAP in 
sepsis comes mainly form an increase in cardiac output [75].The major concerns in use of 
epinephrine are: higher myocardial oxygen demand, hyperglycemia,increased lactate levels 
and a reduction in regional blood flow[76-79].  
Myburhg and colleagues performed a prospective multicenter, double blinded and 
randomized control trial in 280 ICU patients comparing epinephrine to norepinephrine 
founding no difference in the time to achieve arterial pressure goals, 28 day mortality, 90 
day mortality.However, 13% of the patients in the epinephrine group were withdrawn from 
the study because lactic acidosis or tachycardia[84]. 
Another randomized control trial conducted by Annane and colleagues compared 330 
patients with septic shock and evaluated the efficacy of norepinephrine with or without 
dobutamine against epinephrine alone [85]. They found that there was no difference in 
efficacy or safety between the two groups. For instance,epinephrine is not currently 
recommended as fist line vasopressor therapy in view of concerns about tachyarrhythmias 
and his effects on gastric perfusion. 
12. Phenylephrine 
Phenylephrine works at the ǂ1 receptors causing increased blood pressure by 
vasoconstriction. Its use in septic shock has had controversial results but so far there has 
been only few related studies. 
In comparison with norepinephrine, phenylephrine reduces splanchnic blood flow, oxygen 
delivery and lactate uptake [86].On the other hand,it may be a good option when 
tachyarrhythmias limit therapy with other vasopressors. 
13. Vasopressin  
Arginine-vasopressin is an endogenous hormone that is release in response to decrease 
intravascular volume and increase plasma osmolality. Vasopressin constrict vascular 
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smooth muscle though V1 receptors. It also increases the responsiveness of the vascular bed 
to catecholamines [87,88] . Vasopressin may also increase blood pressure by inhibiting 
vascular smooth muscle nitric oxide [89] production and K +-ATP channels [90]. 
A newer interest has emerged as an additive vasoconstrictor in patients with septic shock 
resistant to catecholamines [90]. Vasopressin have been found to be in lower levels than 
expected in patients with septic shock, suggesting relative deficiency. Its combination with 
norepinephrine increases the splanchnic flow and urinary output [91]. Several small-
randomized studies comparing vasopressin with norepinephrine have demonstrated that 
initiation of it decreases catecholamine requirements [92]. 
A large, multicenter, randomized trial (VASST) [97] with 778 patients was done to determine 
whether norepinephrine and vasopressin decreases mortality compared with norepinephrine 
alone. No difference was found in mortality, ICU or hospital length of stay, discontinuation of 
vasopressors or organ dysfunction. The use of norepinephrine infusion was significantly lower 
in cases with vasopressin dose of 0.03U/min, but vasopressin seems to be better in less severe 
group. New retrospective analysis of the VASST suggests a beneficial effect between 
vasopressin and corticosteroid in patients with septic shock that were also treated with 
steroids. Patients with vasopressin with corticosteroids have significantly increased in plasma 
vasopressin levels. Vasopressin at 0.03u/min added to norepinephrine seems to be as safe as 
effective as norepinephrine in fluid resuscitated patients with septic shock.  
14. Dobutamine 
Is an inotrope that has variable effects on blood pressure due to ǃ1 and ǃ2 adrenergic 
agonist effect resulting in an increase heart rate and cardiac contractility. Dobutamine 
should be considered in patients who have low cardiac output in the presence of adequate 
ventricular filling pressures and appropriate mean arterial pressure [28-29] . 
In septic patients, it increases oxygen delivery and consumption. As part the early  
goal directed therapy dobutamine was associated with significant absolute reduction in 
mortality [28]. 
An inotrope should be considered to maintain an adequate cardiac index, mean arterial 
pressure, mixed venous oxygen content and urine output . Other available agents includes 
phosphodisterase inhibitors such as milrinone and enoximone, and calcium sensitizers such 
as levosimedan. There are currently inadequate data to recommend them in septic shock. 
15. Severe sepsis/septic shock and the use of steroids 
Sepsis syndrome is characterized by having a disequilibrium between pro- inflammatory 
and anti-inflammatory cytokines leading to overproduction of IL-1, IL-6 and TNF-ǂ from 
the lymphocytes, macrophages and endothelial cells [100] . It is known that TNF- alfa and 
IL-6 decreases cortisol levels from the adrenal gland and ACTH production from the 
pituitary gland resulting in secondary adrenal insufficiency in approximately 16.3 to 55% of 
patients [101] . Systemic steroids might then have a beneficial role by inhibiting pro-
inflammatory cytokines, nitric oxide and phospholipase A2 [102] . They also enhance the 
activity of adrenergic receptors and increased myocardial contractility resulting in 
improvement of hemodynamics response.  
Hydrocortisone is usually the steroid of choice because it is the synthetic derivative of 
cortisol and also has intrinsic mineralocorticoid activity. After the study by Schumer, a short 
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course of high- dose corticosteroids became an accepted therapy [103] . Subsequent studies, 
however, did not confirm a survival benefit with this regimen and suggested an increase in 
superinfection-related mortality were patients went from being immunomodulated to being 
immunosupressed.  
Multiple randomized trials in patients with septic shock confirm that low-dose steroid 
therapy in these patients improves blood pressure, thereby, causing reduction in 
vasopressor support.  
In 2002 Annane demonstrated a reduced mortality (p=0.04) in a subgroup of patients that 
were non responders to an adrenocorticotropic hormone tests (ACTH test) but the mortality 
rate was increased (p=0.96) in patients without evidence of relative adrenal insufficiency 
(responders) [104] . In 2008 Russell found out a reduced mortality in a subgroup of patients 
with severe septic shock in those receiving steroids and vasopressin versus norepinephrine 
and steroids raising the concern that vasopressin may increase the levels the intrinsic 
cortisol levels [105].  
Bauer found a positive interaction of vasopressin and corticosteroids in a nonrandomized 
cohort study of patients with septic shock, all of whom received vasopressin. Patients who 
received corticosteroids and vasopressin had lower mortality rates (47.6% vs. 80.9%;  
p = 0.02) compared with patients who did not receive corticosteroids with vasopressin. 
Furthermore, a randomized, blinded, placebo-controlled trial (n =100) of vasopressin plus 
corticosteroids or placebo in human cardiac arrest found a beneficial interaction of 
vasopressin and corticosteroids . Patients who received vasopressin plus corticosteroids had 
more frequent return of spontaneous circulation (81% vs. 52%; p =.003) and higher survival 
rates (19% vs. 4%, p = .02) than patients who received vasopressin plus placebo.  
Finally a multicenter, randomized, double-blind, placebo-controlled study called 
Corticosteroid Therapy of Septic Shock (CORTICUS) study, evaluated the efficacy and 
safety of low-dose hydrocortisone therapy in a broad population of patients with septic 
shock[106] . The use of low-dose hydrocortisone had no significant effect on the rate of 
death in 251patients with septic shock versus placebo at 28 days, regardless of the patients’ 
adrenal responsiveness to corticotropin. The proportion of patients in whom reversal of 
shock was achieved was similar in the two groups, though this goal was achieved earlier in 
patients who received hydrocortisone. On the basis of these findings, hydrocortisone cannot 
be recommended as general adjuvant therapy for septic shock (vasopressor responsive), nor 
can corticotropin testing be recommended to determine which patients should receive 
hydrocortisone therapy. Hydrocortisone may have a role among patients who are treated 
early after the onset of septic shock who remain hypotensive despite the administration of 
high-dose vasopressors and adequate fluid resuscitation.  
16. Activated protein C and its role in severe sepsis/septic shock 
Sepsis is associated with alterations in the blood coagulation, fibrinolytic systems and 
inflammatory pathway. This leads to disorders of tissue perfusion that generate multiple 
organ system failure with depletion of platelets and coagulation factors along with the 
activation of natural inhibitors of coagulation. Activated protein C (APC) , an endogenous 
protein that promotes fibrinolysis and inhibits thrombosis and inflammation, is an 
important modulator of the coagulation and inflammation associated with severe 
sepsis[107] . It is converted from its inactive precursor, protein C, by thrombin coupled to 
thrombomodulin. The conversion of protein C to activated protein C may be impaired 
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during sepsis as a result of the down-regulation of thrombomodulin by inflammatory 
cytokines. Reduced levels of protein C are found in the majority of patients with sepsis and 
are associated with an increased risk of death.  
A randomized, double-blind, placebo-controlled, multicenter trial was conducted with 
recombinant human activated protein C in 1998 in 1690 patients to evaluate mortality at 28 
days [108]. The PROWESS (Protein C worldwide evaluation in severe sepsis) trial was 
completed in 2001 and statistical analysis indicated a decreased 28th mortality rate of 30.8% 
in the placebo group compared with 24.7% in the drotrecogin alfa group. The difference in 
the mortality was limited to patients with a higher risk of death, that is, APACHE II scores  
> 25. In these groups mortality was reduced from 44% in the placebo group to 31% in the 
treatment group. Efficacy was doubtful in patients with low risk for death and serious 
bleeding was higher in the APC group.  
In 2005 the ADRESS trial evaluated the efficacy of APC in patients with APACHE score < 25 
or single organ failure and there was no difference in mortality among both groups at 28 
days [109].  
There is increased risk for serious bleeding and no beneficial effect in those patients with 
low risk for death, such as those with single organ failure or an APACHE II score less than 
25 [110]. 
More recently a Cochrane database submitted their review on APC and again no difference 
in mortality was observed in approximately 4434 adults with sepsis. Increased risk for 
serious bleeding was noted and for this reason a new trial was requested by the FDA that 
should be completed at the end of 2011.  
On the basis of this findings APC is recommended for patients with severe sepsis and high 
risk for death if there is no contraindications.  
17. Glucose control in ICU 
Blood glucose control was originally investigated in the setting of diabetes because 
uncontrolled levels seemed to predisposed to multiple infections (e.g., cellulitis, 
postoperative wound infections). Although the exact pathogenesis was unknown, it was 
speculated that the increased risk of infection was related to decreased cellular immune 
function [111]. Later studies (both in animals and humans) demonstrated that the depressed 
ability to fight off infection was a result of impaired polymorphonuclear leukocyte function, 
chemotaxis, and phagocytosis.  
Extensive observational data have shown a consistent, almost linear relationship between 
blood glucose levels in hospitalized patients and adverse clinical outcomes, even in patients 
without established diabetes [112].  
Van den Berghe reported a dramatic 42% relative reduction in mortality in the surgical ICU 
when blood glucose was normalized to 80 to 110 mg per deciliter (4.4 to 6.1 mmol per liter) 
by means of insulin infusion in a prospective, randomized fashion [113]. Five years later, the 
same investigators reported findings from their medical ICU, revealing no mortality benefit 
from intensive glucose control, except in a subgroup requiring critical care for 3 or more 
days [114]. 
A parallel-group, randomized, controlled trial involving adult medical and surgical patients 
admitted to the ICUs of 42 hospitals was conducted from December 2004 through 
November 2008 to evaluate mortality in patients assigned to tight glucose control versus 
conventional glucose control (NICE SUGAR Trial)[115] . Ninety days after randomization, 
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829 of 3010 patients (27.5%) in the intensive-control group had died, as compared with 751 
of 3012 patients (24.9%) in the conventional-control group. Severe hypoglycemia was 
significantly more common with intensive glucose control. In the basis of this findings, 
glucose control with intravenous insulin should be started in patients with severe sepsis 
upon stabilization at ICU when glucose levels are above 180 (1B) with a goal blood glucose 
target in the range of 150 mg/dL (2C). The American Association of Clinical 
Endocrinologists recommends a glucose range of 140 to 180 mg/dL for most hospitalized 
persons.  
18. Mechanical ventilation in sepsis  
The strategies to ventilate patients with severe sepsis have been changing for the last 
decades. Multiple studies demonstrated that ventilating with the usual tidal volume may 
have detrimental effects causing what is now recognized as ventilator induced lung injury. 
This complication have led to new forms of ventilation called lung protective management 
in which lower volumes are provided in order to prevent alveolar overdistention. 
Sepsis itself can induce acute lung injury (ALI) in about 50% of the cases. ALI is defined as 
an acute onset insult resulting in bilateral radiographic infiltrates, pulmonary artery wedge 
pressure ≤ 18 mm Hg when measured by a pulmonary catheter, an echocardiogram 
showing no evidence of left atrial hypertension, and an arterial oxygen tension to fraction of 
inspired oxygen ratio (PaO2/FiO2) of 201 to 300 mmHg. The difference between ARDS is 
mainly the worsening of hypoxemia having above ratio less than 200 mmHg [116]. 
With conventional ventilation,patients with ARDS had higher mortality rate when used 
prior the new recommendations. Lung protective ventilation has shown a decrease 
mortality rate and ventilator-induce lung injury [117]. This intervention also know as low 
tidal volume ventilation involved an initial tidal volume of 6 ml/kilogram of predicted body 
weight (PBW) aiming for a plateau pressure of ≤ 30 cm H2O.  If plateau pressure remains > 
30 after reduction of tidal volume, it should be reduced further to as low as 4 ml/kg PBW 
[118]. In contrast to the conventional ventilation that involved a tidal volume of 12 
ml/kilogram of body weight with low positive end-expiratory pressure (PEEP), protective 
ventilation avoids alveolar overdistention and end-expiratory collapse [119]. The titration of 
the PEEP should approach a balance between lung recruitment and overdistention, 
barotrauma, and hypotension in order to maintain adequate oxygenation (arterial oxygen 
saturation over 88%). This permit lower FIO2, decreasing the risk of oxygen toxicity. High 
PEEP level may increase airway pressures and lung volumes, which could contribute to 
ventilator induced lung injury from overdistention [120]. The optimal strategy to set PEEP 
has not been established [118,120,121].  
The low tidal volume ventilation can result in respiratory acidosis which now is known as 
permissive hypercapnia. The respiratory rate is usually increased to keep adequate minute 
ventilation. The increase on carbon dioxide can cause vasodilation, increase in heart rate, 
cardiac output, blood pressure, pulmonary vascular resistance and decrease renal blood 
flow; but modest hypercapnia has been demonstrated to be safe in clinical trials. This 
ventilation is allowed in order to prevent pulmonary overdistention and consequently 
negative effect in ALI/ARDS [122].If severe respiratory acidosis, pH < 7.15, develops the 
infusion of sodium bicarbonate may be considered. These type of ventilation is 
contraindicated in patients with cerebral disorders such as cerebrovascular insults, trauma, 
or space-occupying intracranial lesions because it may increase the intracranial pressure. 
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In patients with refractory hypoxemia, prone position ventilation has been recommended 
despite no benefits in survival. Proper precautions should be taken to avoid complications 
like pressure sores, accidental dislodgment of the endotracheal tube and central venous 
catheters [118]. Same results has been noticed in studies with high frequency oscillatory 
ventilation and Extra Corporeal Membrane Oxygenation (ECMO). 
Noninvasive ventilation (NIV) has been suggested in patients with ALI/ARDS since it 
allows better communication, reduces incidence of infection, requirements for sedation and 
duration of intensive care unit stay [124]. Its use should be considered only in 
hemodynamically stable patients who are cooperative, able to protect the airway and 
spontaneously clear the airway of secretions; and who are anticipated to recover rapidly 
from the precipitating insult [124]. Continuous positive airway pressure (CPAP) and 
noninvasive positive pressure ventilation (NIPPV) are the most commonly used modes. In 
NIPPV, two different pressures are used: inspiratory positive airway pressure (IPAP) and 
expiratory positive airway pressure (EPAP), whereas CPAP maintains a constant positive 
airway pressure throughout the respiratory cycle. NIPPV may confer an advantage over 
CPAP by reducing the work of breathing during inspiration by providing additional 
inspiratory pressure. The main goal of NIV in patients with ALI/ARDS includes 
improvement of hypoxemia, to unload the respiratory muscles and eventually relieve 
dyspnea. A practical approach has been postulated, it should be use judiciously in selected 
patients to prevent decrease in survival if intubation is delayed [124]. 
The discontinuation of mechanical ventilation crucial and should be base on weaning 
protocol to assess readiness of successful extubation, reducing the duration and the 
complications related to it [118]. 
19. Sedation, analgesia, and neuromuscular blocked in sepsis 
Patients critically ill with sepsis usually require control of anxiety, agitation and pain, 
especially when they are with mechanical ventilation support.There are several options of 
sedative-analgesic medications including benzodiazepines,opioids and neuroleptics. The 
intention is to achieve adequate comfort and safety using protocols with a sedation goal [125].  
This accomplishment should be use according to the patient clinical condition. Several 
scoring scale has been validated, none superior to the other; Riker Sedation-Agitation Scale 
(SAS), Motor Activity Assessment Scale (MAAS), Minnesota Sedation Assessment Tool 
(MSAT), and Richmond Agitation-Sedation Scale (RASS) and Ramsay Sedation Scale [126]. 
The use of protocol-directed sedation can reduce the duration of mechanical ventilation, the 
intensive care unit and hospital lengths of stay, and the need for tracheostomy [127]. The use 
of the combination of spontaneous awakening trials (SATs), daily interruption of sedatives, 
with spontaneous breathing trials (SBTs) for the management of mechanically ventilated 
patients in intensive care results in better outcomes. It can also decrease mechanical 
ventilation, intensive care and hospital stay with survival improvement [128]. 
The pain management should be assessed frequently using a pain scale appropriate to 
patient’s condition. The numeric rating scale has been recommended in critical ill patients 
because it is easier to apply [126]. Patients who cannot communicate behavioral pain scale 
(BPS) may be used. The pain intensity is evaluated by facial expression, movement of the 
upper extremities and compliance with ventilation [129]. 
The neuromuscular blocking agents (NMBAs) are not recommended, when possible, in 
septic patients due to prolonged neuromuscular blocked following discontinuation [125]. 
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They should be use when appropriate sedation and analgesia cannot be achieved. The 
indications are to facilitate mechanical ventilation, improving chest wall compliance, 
preventing respiratory dys-synchrony, reducing peak airway pressures and decrease 
oxygen consumption by reducing work of breathing (1, 6). Patients receiving NMBAs 
should be assessed both clinically and by train-of-four monitoring, a peripheral nerve 
stimulation test, with a goal of adjusting the degree of neuromuscular blockade to achieve 
one or two twitches from a scale of 0 to 4. This may reduce clinical recovery delay from 
NMBAs [125,130]. The administration of NMBAs in early ARDS was demonstrated to 
improve outcomes, it can decrease duration of mechanical ventilation, hospital stay and 
ventilation induce lung injury. Further studies are requiring before this clinical practice can 
be adopted [131]. 
The ‘ABCDE’ bundle has been proposed combining evidence-based interventions. It consist 
of A wakening and Breathing trial coordination, Choice of sedatives and analgesics, Daily 
delirium monitoring, Early mobility and exercise to improve the management of 
mechanically ventilated patients[132]. 
20. Acute kidney injury and sepsis 
Acute kidney injury (AKI) is a common complication of sepsis and septic shock. 
Approximately 35 to 50% of the cases in the ICU can be attributed to sepsis [133 ] Patients 
with sepsis related AKI have higher hospital mortality, 74 % ,compared with a 45% due to 
other diagnosis [ 134 ]. If renal replacement therapy is required the mortality rate rises 
further to as high as 80% [ 135 ]. 
The diagnosis of acute kidney injury, previously termed acute renal failure, is based on an 
elevation in the serum creatinine (SCr) levels. Many definitions have been proposed 
throughout the years since there was no real consensus on the degree of elevation required for 
the diagnosis of AKI. Because of this variability there was the need to develop a classification 
system that could propose a uniform definition within the medical community. 
The Acute Dialysis Quality Initiative’s “RIFLE” (Risk, Injury, Failure, Loss, ESRD) criteria 
was first established and included five categories, the first three of which define AKI and its 
severity largely by percentage increases in SCr over baseline [ 136]. The Acute Kidney Injury 
Network (AKIN) criteria was then proposed and [ 137 ] includes three stages, the last two of 
which are identical to the RIFLE criteria. Both definitions also incorporate severity and 
duration of oliguria as alternative criteria. 
An improvement in urine output is a sensitive indicator of AKI, with an oliguric  
AKI associated to a poorer prognosis. Documentation of urine volume should be of general 
practice in the management of any acutely ill patient, especially those with sepsis or septic 
shock.  
21. Renal replacement therapy 
The decision to start renal replacement therapy (RRT) in patients with AKI should be based 
on the clinical aspects after careful evaluation of fluid, electrolyte and metabolic status of 
each individual patient. 
Currently there are no evidence-based guidelines to suggest an optimal time to initiate 
treatment; it continues to be a clinical decision after the diagnosis of AKI is confirmed and 
before overt complications develop. 
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22. Continuous Renal Replacement Therapy (CRRT) vs. Intermittent 
Hemodyalisis (IHD) 
Intermittent hemodialysis-associated hypotension is estimated to occur in approximately 
20–30% of treatments. Some of the causes are dialysis specific, such as excessive or rapid 
volume removal, changes in plasma osmolality, autonomic dysfunction, and anaphylactic 
membrane reactions [ 138 ]. CRRT is most frequently used in patients who are 
hemodynamically unstable, usually because of sepsis or severe cardiac dysfunction because 
it closely resembles normal physiologic renal function with slow correction of metabolic 
derangements and slow fluid removal. Despite this there is no clear evidence to support the 
superiority of either technique, regarding mortality in the ICU. Clinicians should choose a 
technique according to individual patient characteristics, nursing proficiency, and technical 
resources. 
23. Sodium bicarbonate replacement in sepsis 
Infusions of sodium bicarbonate long have been advocated to correct persistent metabolic 
acidosis. It was said to result in increased pH with less cellular dysfunction, improved cardiac 
contractility and the activity of vasopressor agents. However clinical studies suggest that this 
therapy should be tried as a last resort to improve the patient's clinical status.  
In a recent review [ 139 ] the data supporting sodium bicarbonate infusion were evaluated. 
It seems clear from animal data that artificially increasing the pH does not improve such 
parameters as cardiac function or weaning of vassopressor agents. Further decrease in 
serum pH levels is possible since sodium bicarbonate is converted to carbon dioxide and 
water, which can also lead to sodium and fluid overload. Sodium bicarbonate replacement 
should be considered as a last resource and is not recommended in patients with 
hypoperfusion induced lactic acidema with pH _> 7.15.  
24. Venous thromboembolic events prophylaxis 
Patients with severe sepsis have higher risk of venous thromboembolic events (VTEs) due to 
one or more risk factors, including advanced age, chronic cardiopulmonary disease, recent 
surgery, immobilization, in-dwelling vascular catheters, and previous VTE history [ 140 ]. 
Sepsis is associated with systemic activation of coagulation and frequently results in 
disseminated intravascular coagulation (DIC) [ 141 ]. Also hypoperfusion and reperfusion 
seen in patients with shock has been associated with endothelial damage. Indeed, VTE 
prophylaxis using unfractionated heparin (UFH), low molecular weight heparin (LMWH), 
and/or mechanical methods has become standard of care in most institutions [ 142 ]. 
25. Stress ulcer prophylaxis 
Stress ulcers are a common complication in ICU admissions and more importantly in those 
related to sepsis. A clear etiology has not been established but ischemia and reperfusion are 
thought to cause the mucosal defenses to break down, resulting in mucosal injury and 
ulceration [ 143 ]. During sepsis and septic shock, reduced blood flow, hypoperfusion, and 
reperfusion injury may be seen secondary to hypotension or hypovolemia. These are the 
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Treatment options include H2 receptor antagonists (H2Ras) which act by decreasing gastric 
acid secretion through reversible, competitive inhibition of histamine-stimulated acid 
secretion and are effective in reducing basal acid production. However, because gastrin and 
acetylcholine provide alternative pathways to the stimulation of acid secretion, acid 
suppression with H2RAs is incomplete. 
Proton pump inhibitors (PPIs) inhibit the final step in acid production, the generation of 
gastric hydrogen ions via hydrogen potassium adenosinetriphosphatase; they provide long-
lasting suppression of acid secretion. 
Both H2Ras and PPIs have been proved effective for prevention of stress ulcers and 
superiority of one treatment option over the other has not been clearly established in clinical 
trials. Careful considerations must be taken on greater incidence of ventilator associated 
pneumonias on patients with sepsis already placed on mechanical ventilation, due to an 
increase in stomach pH. Physicians most weight individual risk over benefits, especially in 
those patients at greater risks of developing gastrointestinal bleeding. 
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